MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/keab249

Медицинская библиотека · Rheumatology (Oxford, England) · 2021

Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study.

Weill Amandine, Delyon Julie, Descamps Vincent, Deschamps Lydia, Dinulescu Monica, Dupuy Alain, Célérier Philippe, Nardin Charlee, Aubin François, Le Corre Yannick, Heidelberger Valentine, Maubec Eve, Malissen Nausicaa, Longvert Christine, Machet Laurent, Gounant Valérie, Brosseau Solenne, Bonniaud Bertille, Jeudy Géraldine, Psimaras Dimitri, Doucet Ludovic, Lebbe Céleste, Zalcman Gérard, De Masson Adèle, Baroudjian Barouyr, Leonard-Louis Sarah, Hervier Baptiste, Brunet-Possenti Florence, Groupe de Cancérologie Cutanée and PATIO Group

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

OBJECTIVES

The occurrence of immune-related myositis (irM) is increasing, yet there are no therapeutic guidelines. We sought to analyse the current therapeutic strategies of irM and evaluate the outcomes of immune checkpoint inhibitors (ICIs) rechallenge.

METHODS

We conducted a nationwide retrospective study between April 2018 and March 2020 including irM without myocardial involvement. Depending on the presence of cutaneous signs or unusual histopathological features, patients were classified into two groups: typical or atypical irM. Therapeutic strategies were analysed in both groups. The modalities and outcomes of ICI rechallenge were reviewed.

RESULTS

Among the 20 patients, 16 presented typical irM. Regardless of severity, most typical irM were treated with steroid monotherapy (n = 14/16) and all had a complete response within ≤3 weeks. The efficacy of oral steroids for non-severe typical irM (n = 10) was the same with low-dose (≤0.5 mg/kg/day) or high-dose (1 mg/kg/day). Severe typical irM were successfully treated with intravenous methylprednisolone. Atypical irM (n = 4) had a less favourable evolution, including one irM-related death, and required heavy immunosuppression. ICIs were safely reintroduced in nine patients presenting a moderate (n = 6) or a severe (n = 3) irM.

CONCLUSION

Our data highlight that steroid monotherapy is an effective treatment for typical irM, either with prednisone or with intravenous methylprednisone pulses depending on the severity. The identification of unusual features is important in determining the initial therapeutic strategy. The outcomes of rechallenged patients are in favour of a safe reintroduction of ICI following symptom resolution and creatin kinase (CK) normalization in moderate and severe forms of irM.

Для цитирования: Weill Amandine, Delyon Julie, Descamps Vincent, Deschamps Lydia, Dinulescu Monica, Dupuy Alain, Célérier Philippe, Nardin Charlee, Aubin François, Le Corre Yannick, Heidelberger Valentine, Maubec Eve, Malissen Nausicaa, Longvert Christine, Machet Laurent, Gounant Valérie, Brosseau Solenne, Bonniaud Bertille, Jeudy Géraldine, Psimaras Dimitri, Doucet Ludovic, Lebbe Céleste, Zalcman Gérard, De Masson Adèle, Baroudjian Barouyr, Leonard-Louis Sarah, Hervier Baptiste, Brunet-Possenti Florence, Groupe de Cancérologie Cutanée and PATIO Group. Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study.. Rheumatology (Oxford, England). 2021. DOI: 10.1093/rheumatology/keab249.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.